GBS Inc. to Present First Quarter 2022 Financial Results and Recent Corporate Update on November 11
GBS Inc., a life sciences company focusing on non-invasive diagnostic testing, will announce its financial results for the first quarter ending September 30, 2021, after the market closes on November 11, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
GBS Inc., a life sciences company focusing on non-invasive diagnostic testing, will announce its financial results for the first quarter ending September 30, 2021, after the market closes on November 11, 2021. Following this, management will host a conference call at 4:30 p.m. ET to discuss the results. Investors and stakeholders can access the live webcast on the company's website. GBS is known for its innovative Biosensor Platform aimed at improving diabetes care.
Details
News Market Reaction – GBS
The recorded move for GBS in the trading session of this news was -2.65%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company to Host Conference Call & Webcast at 4:30 p.m. ET
NEW YORK, Nov. 01, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that it will release its financial results for the first quarter ended September 30, 2021, shortly after the NASDAQ market close on Thursday, November 11. Management will then host a conference call and webcast at 4:30 p.m. ET.
| Title: | GBS, Inc. First Quarter 2022 Financial Results Conference Call & Webcast |
| Date: | Thursday, November 11, 2021 |
| Time: | 4:30 p.m. ET |
| Conference Call Details: | Toll-Free: 877-407-3982 International: 201-493-6780 Conference ID: 13724335 |
| The conference call will be webcast live from the Company’s website and will be available via the following links: | |
| Webcast: | Webcast Registration Link https://78449.themediaframe.com/dataconf/productusers/vvdb/mediaframe/47098/indexl.html https://investors.gbs.inc/news-and-events/investor-calendar |
| The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Company’s website. | |
About GBS Inc.
GBS Inc. is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. With the world-first Biosensor Platform, GBS Inc. is developing and launching diagnostic tests urgently needed to help people living with diabetes. For more information, please visit GBS.inc.
Investor Contact:
Tim McCarthy – Managing Director
LifeSci Advisors, LLC
Tim@LifeSciAdvisors.com
Company Contact:
Spiro Sakiris – Chief Financial Officer
GBS, Inc.
Investor.Relations@gbs.inc
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.